News

Genentech and AC Immune partner again
Enlarge image

BusinessSwitzerland

Genentech and AC Immune partner again

19.06.2012 - Six years after their first alliance, Swiss AC Immune SA partners again with US-American Genentech Inc.

Basel/Lausanne – The subject of the new cooperation remained the same: fighting Alzheimer's disease. Therefore the Roche subsidiary has now in-licensed a second generation of AC Immune's antibodies - this time directed to bind the Tau protein. Under the terms of the agreement, AC Immune will receive an undisclosed upfront payment and research, development and commercialisation milestone payments totalling more than CHF400m. Additionally, AC Immune could pocket royalties on net sales resulting from the collaboration – if the product is approved.

Under the multi-year joint research collaboration, AC Immune will work in partnership with Genentech to identify and formulate several pre-clinical candidates. The pharma will have global responsibility for pre-clinical and clinical development, manufacturing and commercialisation of antibodies resulting from the collaboration. Scientifically, both partners are building on the first alliance as the new Tau antibodies are thought to flank Crenezumab, an antibody in phase II resulting from the first cooperation that binds amyloid-beta-plaques (abeta).

By blocking Tau- fibrillation and destroying abeta aggregates, AC Immune attacks the two crucial steps in Alzheimer development. AC Immune has raised CHF64m since its foundation in 2003. Financiers are business angels from Switzerland and prominent biotech supporters like Dietmar Hopp, the founder of the German business software maker SAP. Beside the out- licensed antibody projects, AC immune develops a proprietary small molecule pipeline

http://www.european-biotechnology-news.com/news/news/2012-02/genentech-and-ac-immune-partner-again.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. However, a preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

Drug AssessmentPortugalFrance

18.01.2016 A Phase I clinical trial for a drug developed by Portuguese pharma company Bial has ended in disaster. One man died, five others may have irreversible neurological damage.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SAREUM HOLDINGS (UK)0.25 GBP8.70%
  • MAGFORCE (D)5.25 EUR5.00%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • EVOCUTIS (UK)0.07 GBP-12.50%

TOP

  • VERONA PHARMA (UK)3.50 GBP32.1%
  • WILEX (D)2.09 EUR22.9%
  • IXICO (UK)34.00 GBP15.3%

FLOP

  • BIONOR PHARMA (N)0.88 NOK-43.6%
  • PROTHENA PLC (IE)34.27 USD-36.4%
  • PLETHORA (UK)2.75 GBP-33.3%

TOP

  • KARO BIO (S)26.80 SEK3728.6%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • 4SC (D)3.33 EUR291.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.80 SEK-85.6%
  • BIOTEST (D)14.11 EUR-84.5%
  • EVOCUTIS (UK)0.07 GBP-75.0%

No liability assumed, Date: 07.02.2016